Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XFOR |
---|---|---|
09:32 ET | 38772 | 0.94 |
09:34 ET | 41162 | 0.9401 |
09:36 ET | 2646 | 0.94 |
09:38 ET | 131 | 0.9489 |
09:39 ET | 9119 | 0.9588 |
09:41 ET | 40000 | 0.9499 |
09:43 ET | 1814 | 0.95 |
09:45 ET | 204 | 0.9501 |
09:48 ET | 4035 | 0.9501 |
09:50 ET | 7100 | 0.9559 |
09:52 ET | 4269 | 0.9503 |
09:54 ET | 3099 | 0.9561 |
09:56 ET | 1461 | 0.956 |
09:57 ET | 9302 | 0.95 |
09:59 ET | 500 | 0.941 |
10:01 ET | 1523 | 0.9448 |
10:03 ET | 5104 | 0.9497 |
10:06 ET | 6186 | 0.9494 |
10:08 ET | 5900 | 0.9449 |
10:10 ET | 6063 | 0.9494 |
10:12 ET | 11868 | 0.94 |
10:14 ET | 19428 | 0.9389 |
10:15 ET | 10188 | 0.9387 |
10:17 ET | 7203 | 0.9301 |
10:19 ET | 35050 | 0.9363 |
10:21 ET | 72254 | 0.9296 |
10:24 ET | 4793 | 0.9208 |
10:26 ET | 15584 | 0.9357 |
10:28 ET | 3200 | 0.938 |
10:30 ET | 1450 | 0.9397 |
10:32 ET | 36071 | 0.93257 |
10:33 ET | 1489 | 0.9326 |
10:35 ET | 2726 | 0.93195 |
10:37 ET | 12973 | 0.9251 |
10:39 ET | 4978 | 0.921 |
10:42 ET | 70211 | 0.9299 |
10:44 ET | 15950 | 0.9255 |
10:46 ET | 8108 | 0.9297 |
10:48 ET | 3210 | 0.9298 |
10:50 ET | 1328 | 0.929799 |
10:51 ET | 24225 | 0.936 |
10:53 ET | 3000 | 0.93905 |
10:55 ET | 15065 | 0.9551 |
10:57 ET | 33290 | 0.9501 |
11:00 ET | 1433 | 0.9473 |
11:04 ET | 805 | 0.947 |
11:06 ET | 128 | 0.9445 |
11:08 ET | 900 | 0.9395 |
11:09 ET | 7860 | 0.9387 |
11:11 ET | 5100 | 0.9408 |
11:13 ET | 6165 | 0.9368 |
11:18 ET | 3368 | 0.9335 |
11:20 ET | 8843 | 0.9401 |
11:24 ET | 1000 | 0.94 |
11:26 ET | 5124 | 0.9474 |
11:27 ET | 400 | 0.94 |
11:29 ET | 2014 | 0.94 |
11:31 ET | 100 | 0.9425 |
11:33 ET | 700 | 0.9419 |
11:36 ET | 9800 | 0.9419 |
11:38 ET | 1765 | 0.9407 |
11:40 ET | 5600 | 0.94 |
11:42 ET | 1009 | 0.9401 |
11:44 ET | 800 | 0.94 |
11:45 ET | 2300 | 0.94 |
11:47 ET | 14900 | 0.9351 |
11:49 ET | 4600 | 0.9303 |
11:51 ET | 12402 | 0.9402 |
11:54 ET | 350 | 0.9374 |
11:56 ET | 5200 | 0.9413 |
11:58 ET | 100 | 0.94105 |
12:00 ET | 25600 | 0.9301 |
12:02 ET | 1400 | 0.9298 |
12:03 ET | 800 | 0.93 |
12:05 ET | 3875 | 0.93 |
12:07 ET | 2960 | 0.9301 |
12:09 ET | 400 | 0.9301 |
12:12 ET | 100 | 0.9404 |
12:14 ET | 1228 | 0.9401 |
12:16 ET | 1131 | 0.940599 |
12:18 ET | 1685 | 0.9399 |
12:20 ET | 700 | 0.9395 |
12:21 ET | 1300 | 0.937 |
12:23 ET | 9139 | 0.9352 |
12:25 ET | 1400 | 0.9352 |
12:27 ET | 600 | 0.9352 |
12:30 ET | 2586 | 0.9338 |
12:32 ET | 953 | 0.9362 |
12:34 ET | 100 | 0.9351 |
12:36 ET | 50488 | 0.92373 |
12:38 ET | 5649 | 0.9371 |
12:39 ET | 5000 | 0.937099 |
12:41 ET | 100 | 0.9333 |
12:43 ET | 1232 | 0.9295 |
12:45 ET | 800 | 0.9353 |
12:48 ET | 659 | 0.9333 |
12:50 ET | 437 | 0.9333 |
12:52 ET | 35333 | 0.9318 |
12:54 ET | 12400 | 0.9248 |
12:56 ET | 10720 | 0.9206 |
12:57 ET | 1984 | 0.9279 |
12:59 ET | 3050 | 0.928 |
01:01 ET | 6565 | 0.935 |
01:03 ET | 1900 | 0.9297 |
01:06 ET | 51328 | 0.9203 |
01:08 ET | 400 | 0.9205 |
01:10 ET | 15273 | 0.93 |
01:12 ET | 300 | 0.9325 |
01:14 ET | 3862 | 0.9311 |
01:15 ET | 1108 | 0.9326 |
01:17 ET | 700 | 0.9332 |
01:19 ET | 1300 | 0.9311 |
01:21 ET | 2300 | 0.93115 |
01:24 ET | 700 | 0.9319 |
01:26 ET | 450 | 0.932 |
01:28 ET | 3200 | 0.9322 |
01:30 ET | 950 | 0.9321 |
01:32 ET | 54001 | 0.9286 |
01:33 ET | 2150 | 0.9288 |
01:35 ET | 25300 | 0.9371 |
01:37 ET | 270 | 0.93709 |
01:39 ET | 748 | 0.9203 |
01:42 ET | 842 | 0.92985 |
01:44 ET | 2200 | 0.9292 |
01:46 ET | 3374 | 0.929998 |
01:48 ET | 448 | 0.9294 |
01:50 ET | 7113 | 0.923 |
01:51 ET | 11700 | 0.92145 |
01:53 ET | 20900 | 0.9235 |
01:55 ET | 500 | 0.9233 |
01:57 ET | 8713 | 0.9207 |
02:00 ET | 3290 | 0.92225 |
02:02 ET | 900 | 0.9194 |
02:04 ET | 1579 | 0.9235 |
02:06 ET | 3382 | 0.92105 |
02:08 ET | 1766 | 0.9185 |
02:09 ET | 1249 | 0.9196 |
02:11 ET | 3345 | 0.9183 |
02:13 ET | 3190 | 0.9183 |
02:15 ET | 2500 | 0.9178 |
02:18 ET | 18300 | 0.91845 |
02:20 ET | 3600 | 0.9186 |
02:22 ET | 55609 | 0.9137 |
02:24 ET | 7777 | 0.910401 |
02:26 ET | 7400 | 0.9137 |
02:27 ET | 1200 | 0.9159 |
02:29 ET | 800 | 0.91265 |
02:31 ET | 14796 | 0.9119 |
02:33 ET | 3548 | 0.9132 |
02:36 ET | 9203 | 0.92 |
02:38 ET | 2110 | 0.9186 |
02:40 ET | 500 | 0.9216 |
02:42 ET | 200 | 0.9216 |
02:44 ET | 2451 | 0.9213 |
02:45 ET | 1000 | 0.92169 |
02:47 ET | 148934 | 0.90355 |
02:49 ET | 33405 | 0.9105 |
02:51 ET | 20357 | 0.9168 |
02:54 ET | 100 | 0.9158 |
02:56 ET | 5384 | 0.9122 |
02:58 ET | 9800 | 0.91765 |
03:00 ET | 6700 | 0.9153 |
03:02 ET | 13767 | 0.91 |
03:03 ET | 55112 | 0.9076 |
03:05 ET | 1400 | 0.9088 |
03:07 ET | 2800 | 0.905315 |
03:09 ET | 3076 | 0.9078 |
03:12 ET | 27688 | 0.9201 |
03:14 ET | 14100 | 0.92 |
03:16 ET | 2572 | 0.92015 |
03:18 ET | 5575 | 0.9201 |
03:20 ET | 2000 | 0.9181 |
03:21 ET | 11500 | 0.9199 |
03:23 ET | 7092 | 0.9193 |
03:25 ET | 3889 | 0.918 |
03:27 ET | 4408 | 0.9185 |
03:30 ET | 626 | 0.91765 |
03:32 ET | 2333 | 0.9171 |
03:34 ET | 4500 | 0.918 |
03:36 ET | 2196 | 0.91941 |
03:38 ET | 2453 | 0.9212 |
03:39 ET | 3796 | 0.9252 |
03:41 ET | 770 | 0.92735 |
03:43 ET | 25810 | 0.9319 |
03:45 ET | 8308 | 0.9292 |
03:48 ET | 452 | 0.9298 |
03:50 ET | 400 | 0.92955 |
03:52 ET | 2866 | 0.9297 |
03:54 ET | 7459 | 0.9297 |
03:56 ET | 10187 | 0.9299 |
03:57 ET | 17347 | 0.9314 |
03:59 ET | 14258 | 0.9284 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
X4 Pharmaceuticals Inc | 155.9M | -1.3x | --- |
Gossamer Bio Inc | 157.0M | -0.7x | --- |
Context Therapeutics Inc | 150.0M | -1.5x | --- |
Cardiff Oncology Inc | 162.4M | -4.0x | --- |
Corvus Pharmaceuticals Inc | 143.2M | -4.5x | --- |
Renovaro Inc | 143.1M | -1.3x | --- |
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $155.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 167.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.70 |
Book Value | $0.31 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.